Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
शेयरों में रैंक
#3422
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
शेयर मूल्य
$4.48
मार्केट कैप
$4.99B
बदलाव (1 दिन)
-5.20%
बदलाव (1 वर्ष)
-41.89%
देश
CN
व्यापार Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
श्रेणी
Healthcare
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) के लिए P/B अनुपात
October 2026 को P/B अनुपात TTM: 3.88
Shenzhen Salubris Pharmaceuticals Co., Ltd. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 3.88 है। 2024 के अंत में, कंपनी का P/B अनुपात 3.96 था।
Shenzhen Salubris Pharmaceuticals Co., Ltd. के लिए 2006 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
| वर्ष | P/B अनुपात | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 3.88 | -37.25% |
| 2025 | 6.18 | 56.35% |
| 2024 | 3.96 | -12.84% |
| 2023 | 4.54 | -0.14% |
| 2022 | 4.54 | 25.18% |
| 2021 | 3.63 | -31.38% |
| 2020 | 5.29 | 65.13% |
| 2019 | 3.20 | 5.19% |
| 2018 | 3.05 | -57.11% |
| 2017 | 7.10 | 24.43% |
| 2016 | 5.71 | -16.88% |
| 2015 | 6.86 | 12.33% |
| 2014 | 6.11 | -14.97% |
| 2013 | 7.19 | 11.94% |
| 2012 | 6.42 | 55.67% |
| 2011 | 4.12 | -53.03% |
| 2010 | 8.78 | 74.01% |
| 2009 | 5.05 | -76.40% |
| 2008 | 21.39 | -44.68% |
| 2007 | 38.66 | -13.03% |
| 2006 | 44.45 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
| कंपनी | P/B अनुपात | P/B अनुपात में अंतर | देश |
|---|---|---|---|
| 9.3984 | 142.36% |
US
|
|
| 2.0545 | -47.02% |
FR
|
|
| 8.6921 | 124.14% |
JP
|
|
| 2.1872 | -43.60% |
US
|
|
| 1.5197 | -60.81% |
CH
|
